England & Wales health agency rejects two cancer drugs
Added: Thursday 29 September 2011
The National Institute for Health and Clinical Effectiveness (NICE), which makes recommendations to the NHS in England and Wales, has said that it will probably reject two cancer treatments. NICE has produced draft guidance stating that it could not recommend vinflunine, a treatment for the urothelial tract, or erlotinib, a lung cancer treatment. NICE cited both cost and evidence concerns as reasons for rejecting the drugs.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: